Encouraging Blood Donation in Patients With a Blood Type in Short Supply - Part 2

NCT ID: NCT05825300

Last Updated: 2023-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40486 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-10

Study Completion Date

2023-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to test whether emails that inform patients they have a blood type in need are more effective at encouraging patients to schedule and attend blood donation appointments, compared to email messages that do not mention the patient has a blood type in need.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There has been a years-long national shortage of several blood types in the U.S., including in the Geisinger community. Previously, the study team collaborated with Miller Keystone, where Geisinger refers patients who wish to donate blood and from whom Geisinger receives blood for clinical purposes, on an outreach study to encourage blood donation in patients with needed blood types. The study demonstrated that, compared to a no-message control group, patient portal messages sent to patients with needed blood types increase patients' likelihood of attending donation appointments. However, results were ambiguous with respect to which of two message versions was most effective. One version, which stated that the patient had a needed blood type (blood-type message), caused a numerically, but not significantly, higher number of patients who attended appointments compared to the other version, which did not state that the patient had a blood type in need but rather informed the recipient of a general blood shortage (no-blood-type message).

Because Miller Keystone particularly values reaching new donors, the team ran a preregistered exploratory analysis to test whether the messages were differently effective for new donors compared to those who had previously donated at a Miller Keystone site. There was a significant interaction between previous donor status (previous donor, previous non-donor) and message type, such that previous non-donors were relatively more responsive to the blood-type message, while previous donors were more responsive to the no-blood-type message. However, the groups were uneven with respect to the number of patients that had previously donated. Moreover, when the analysis was limited to patients who opened their messages, this interaction effect disappeared: blood-type messages were still most effective in previous non-donors, and there was no difference in message effectiveness among previous donors. These follow-up analyses, and the unevenness of previous donors across groups, call into question the robustness of the interaction effect.

The present study will again test whether the blood-type message is more effective than the no-blood-type message for patients with needed blood types overall, and separately for previous donors and non-donors. Messages will be sent via email rather than via patient portal in the present study. Randomization will occur at the email-address level to one of the two message types to ensure everyone using the same email address receives the same message (although each patient will be sent an individualized message with their name; there will be no no-contact control condition this time). Email addresses will be excluded if they are shared by patients with different blood types. Randomization will be stratified by whether all patients using the same email address are previous donors or not (email addresses shared by previous donors and non-donors will be excluded).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behavior, Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Caregivers
The patients in the study will not know that other messages are being sent to other patients, although they will see the text of their own message. Providers will be blind to patient conditions.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No-blood-type message

This group will receive a message that does not mention that the patient's blood type is in short supply.

Group Type EXPERIMENTAL

Email message

Intervention Type BEHAVIORAL

Email message encourages patients to donate blood

Blood-type message

This group will receive a message that states their blood type is in short supply.

Group Type EXPERIMENTAL

Email message

Intervention Type BEHAVIORAL

Email message encourages patients to donate blood

Social responsibility

Intervention Type BEHAVIORAL

Message specifies that there is a shortage of the patient's blood type

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Email message

Email message encourages patients to donate blood

Intervention Type BEHAVIORAL

Social responsibility

Message specifies that there is a shortage of the patient's blood type

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented blood type in short supply
* Age 18+
* Can be contacted via email

Exclusion Criteria

* Hemoglobin test result \< 12.5 within the 3 months prior to list creation
* Shares an email address with a patient of a different needed blood type
* Email address associated with at least one previous donor and one non-previous donor
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Geisinger Clinic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amir Goren

Program Director, Behavioral Insights Team

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amir Goren, PhD

Role: PRINCIPAL_INVESTIGATOR

Geisinger Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Geisinger Clinic

Danville, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-0476-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of Reminders on Adherence
NCT02411006 COMPLETED NA